methionine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	3347	63-68-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methionine L-methionine S-methionine	A sulfur-containing essential L-amino acid that is important in many body functions. Molecular weight: 149.21 Formula: C5H11NO2S CLOGP: -1.73 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.80 ROTB: 4

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methionine
L-methionine
S-methionine

A sulfur-containing essential L-amino acid that is important in many body functions.

Molecular weight: 149.21
Formula: C5H11NO2S
CLOGP: -1.73
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -0.80
ROTB: 4

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	76.24	36.49	15	281	7538	63481188
Infantile apnoea	51.44	36.49	8	288	1025	63487701
Selective eating disorder	45.87	36.49	8	288	2064	63486662
Cerebral haemorrhage	41.52	36.49	12	284	30717	63458009

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrolyte imbalance	48.61	38.15	15	524	14397	34941995
Paraplegia	38.83	38.15	9	530	2902	34953490
General physical health deterioration	38.34	38.15	24	515	128245	34828147

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrolyte imbalance	45.33	36.22	15	699	30866	79712808
Paraplegia	38.74	36.22	9	705	5044	79738630
Gaze palsy	37.63	36.22	8	706	2997	79740677
Quadriplegia	36.74	36.22	8	706	3352	79740322

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AB26	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes
ATC	V09IX13	VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:74529	antidotes to acetaminophen poisoning
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:83056	Daphnia magna metabolites
CHEBI has role	CHEBI:84735	algal metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335
Hypertensive disorder	contraindication	38341003	DOID:10763
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Hyperlipidemia	contraindication	55822004	DOID:1168
Heart disease	contraindication	56265001	DOID:114
Hypercalcemia	contraindication	66931009	DOID:12678
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.37	acidic
pKa2	9.44	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
S-ribosylhomocysteine lyase	Unclassified		LUXS_BACSU		Ki	4.21		CHEMBL

External reference:

ID	Source
4018672	VUID
N0000146983	NUI
D00019	KEGG_DRUG
4018672	VANDF
4018991	VANDF
C0025646	UMLSCUI
CHEBI:16811	CHEBI
MET	PDB_CHEM_ID
CHEMBL274119	ChEMBL_ID
CHEMBL42336	ChEMBL_ID
DB00134	DRUGBANK_ID
D008715	MESH_DESCRIPTOR_UI
6137	PUBCHEM_CID
452	INN_ID
4814	IUPHAR_LIGAND_ID
AE28F7PNPL	UNII
6837	RXNORM
5074	MMSL
6044	MMSL
NOCODE	MMSL
d00489	MMSL
002048	NDDF
002867	NDDF
108956002	SNOMEDCT_US
312184007	SNOMEDCT_US
70288006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ProcalAmine	HUMAN PRESCRIPTION DRUG LABEL	22	0264-1915	INJECTION	0.16 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.34 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.34 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.34 g	INTRAVENOUS	NDA	23 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9010	INJECTION, SOLUTION	0.53 g	INTRAVENOUS	NDA	24 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9011	INJECTION, SOLUTION	0.53 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.34 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.20 g	INTRAVENOUS	NDA	23 sections
HepatAmine	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9371	INJECTION, SOLUTION	0.10 g	INTRAVENOUS	NDA	23 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	320 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	200 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	200 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	320 mg	INTRAVENOUS	NDA	20 sections